Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

For decades, Fordham has been one of the world's most filmed universities. Its green quads, collegiate Gothic charm, and ...

OSU Marion graduate, Mount Gilead native Kaitlynn Pfeifer accepted into mock in vitro fertilization lab in North Carolina.

A new study published has revealed that Gilead Sciences’ Lenacapavir has shown promising results as prevention method for HIV with long-lasting effects. The annual injection can be used as a pre ...

NEW YORK (AP) — When protests over the Israel-Hamas war took root on Columbia University’s campus last spring, Mahmoud Khalil became a familiar, outspoken figure in a student movement that ...

Also Read: Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention At CROI 2025, the primary results of a Phase 2 study evaluating lenacapavir (LEN) with teropavimab (TAB) and ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...